Bicycle Therapeutics is shrinking its workforce by about 30% as the company resets priorities around its oncology pipeline and pulls back from its lead program, zelenectide.
The biotech disclosed the move in its March 17 financial report, saying the restructuring is part of a broader strategic reprioritization. Based on a year-end headcount of 288 full-time employees, the reduction could affect roughly 86 positions. A company spokesperson later said about 200 employees will remain after the reorganization.
The decision comes after Bicycle received feedback from the FDA indicating that one of the studies supporting zelenectide is no longer viewed as an acceptable approval route. The company had been aiming to use data from the program to support a filing in metastatic urothelial carcinoma, but that plan is now on hold.
As part of the reset, Bicycle is also winding down two Phase 1/2 trials of zelenectide, including studies in breast cancer and non-small cell lung cancer. Together, the moves suggest the company is tightening focus on programs with a clearer development path while cutting back on work that no longer fits its near-term strategy.
For a biotech built around targeted peptide-drug conjugate technology, the shakeup is significant. Bicycle has long positioned its platform as a way to deliver precision cancer therapies, but the latest restructuring shows how quickly clinical and regulatory setbacks can force a company to rethink both its pipeline and its operating model.
The layoffs add Bicycle to a growing list of biopharma companies making cost-cutting decisions in 2026 as the sector continues to balance cash preservation, regulatory risk, and the pressure to show progress with lead assets.
